TG Therapeutics (NASDAQ:TGTX) shares were up 17.95% at $35.49, gaining $5.40 as of 12:14 PM ET Monday, after the company issued 2025 revenue guidance above expectations and posted a strong Q4 beat.
The biopharma company expects 2025 revenue of ~$540 million, slightly above the $534.45 million consensus estimate. In Q4 2024, revenue came in at $108.19 million, surpassing expectations of $100.67 million.
Adding to investor optimism, TG Therapeutics plans to start a pivotal trial for a subcutaneous version of its multiple sclerosis therapy, Briumvi (ublituximab), by mid-year. The stock has surged over 50% in the past six months, reflecting strong growth momentum as investors remain bullish on the company's potential.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。